BOSTON, Aug. 14, 2026
Cue Biopharma, Inc. reported continued progress across its clinical-stage pipeline, highlighted by the recent Investigational New Drug (IND) submission for CUE-221 to the U.S. FDA for food allergy applications. The company is developing CUE-221 as a potential therapy for immune-mediated diseases, with the program currently advancing through clinical development in allergic diseases. Cue Biopharma also expects to report Phase 2 data for CUE-221 in chronic spontaneous urticaria by the end of the third quarter of 2026, creating an important near-term clinical milestone for the company. CUE-221 is a novel anti-IgE antibody designed to target allergic disease through a differentiated mechanism, and the latest regulatory submission expands its potential development scope beyond the company’s current clinical work. Alongside CUE-221, Cue Biopharma is preparing its next-generation autoimmune program, CUE-401, for clinical development.
CUE-221 Advances Across Allergic Disease Programs
The most significant development during the quarter was the CUE-221 IND submission to the FDA for food allergy applications, marking another step in the expansion of the program. CUE-221 is currently being evaluated in Phase 2 development for allergic diseases, while the company anticipates a clinical data readout in chronic spontaneous urticaria by the end of Q3 2026. The company believes the asset could provide opportunities across multiple immune-mediated allergic conditions. The latest IND submission therefore represents an important regulatory milestone as Cue Biopharma works to broaden the potential clinical application of CUE-221. The company is also continuing to advance its development strategy around the program following its licensing transaction with Ascendant Therapeutics, with resources being directed toward clinical development and pipeline advancement.
CUE-401 Moves Toward First-in-Human Study
Beyond CUE-221, CUE-401 represents another important component of Cue Biopharma’s clinical pipeline. The company expects to submit an IND application and initiate a Phase 1 clinical study by the end of 2026. CUE-401 was developed using the company’s Immuno-STAT platform, which is designed to selectively target disease-specific T cells in vivo without broad immune modulation. The program is intended to regulate inflammation and promote Treg-mediated immune tolerance, potentially providing a differentiated approach to autoimmune diseases. The planned IND submission and Phase 1 initiation would establish another clinical development program for Cue Biopharma and provide an additional milestone beyond the ongoing CUE-221 program. The company has also strengthened its scientific leadership, with Dr. Dominic Borie appointed Chief Medical Officer and Head of Research and Development, bringing additional immunology expertise to support advancement of the pipeline.
Advertisement
$50 Million Financing Supports Clinical Development
Cue Biopharma also completed a $50 million private placement to support clinical development, pipeline advancement and infrastructure expansion. The financing comes as the company prepares for several potential clinical milestones, including the upcoming CUE-221 Phase 2 data readout and the planned CUE-401 Phase 1 program. The company reported $17.4 million in cash and cash equivalents as of June 30, 2026, following one-time cash outflows associated with the CUE-221 licensing transaction, with the subsequent financing providing additional capital for development activities. Second-quarter revenue reached $7.9 million, primarily reflecting milestone-related revenue from the Boehringer Ingelheim collaboration. Cue Biopharma reported a $153.1 million net loss, largely influenced by one-time non-cash charges associated with the Ascendant license agreement and related warrants. With the financing completed and additional leadership appointments in place, the company’s immediate focus remains on advancing CUE-221, reporting upcoming clinical data and moving CUE-401 toward Phase 1 development.
Source:Cue Biopharma press relese
